Enterprise Value

214.3B

Cash

11.93B

Avg Qtr Burn

N/A

Short % of Float

1.24%

Insider Ownership

0.05%

Institutional Own.

68.54%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
TALA + enzalutamide Details
Cancer, Prostate cancer, Castration-resistant prostate cancer

Approved

Update

Approved

Update

Approved

Update

Approved

Quarterly sales

Approved

Quarterly sales

BRAFTOVI + MEKTOVI Details
Cancer, Non-small cell lung carcinoma

Approved

Quarterly sales

Approved

Quarterly sales

PADCEV® Details
Urothelial carcinoma

Approved

Quarterly sales

Approved

Quarterly sales

TUKYSA (Tucatinib) Details
Solid tumor/s, Cancer, Metastatic colorectal cancer, Colorectal cancer

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

ELREXFIO (elranatamab) Details
Cancer, Multiple myeloma

Approved

Quarterly sales

LORBRENA® Details
Cancer, Lung cancer, Non-small cell lung carcinoma

Approved

Quarterly sales

Approved

Quarterly sales

ABRYSVO Details
Respiratory syncytial virus, Respiratory virus

Approved

Quarterly sales

Oxbryta (Voxelotor) Details
SCD (Sickle Cell Disease)

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

VELSIPITY Details
Ulcerative colitis

Approved

Quarterly sales

PDUFA

Approval decision

Aztreonam-Avibactam (ATM-AVI) Details
Pneumonia, Bacterial infection, Intra-abdominal infections

NDA

Submission

Phase 3

Data readout

Phase 3

Data readout

IBRANCE (palbociclib) Details
Cancer, Breast cancer

Phase 3

Data readout

TUKYSA (Tucatinib) combo Kadcyla Details
Cancer, Solid tumor/s, Breast cancer

Phase 3

Update

Phase 3

Update

Troriluzole Details
Obsessive compulsive disorder

Phase 2/3

Data readout

Danuglipron Details
Obesity, Type 2 diabetes

Phase 2b

Data readout

Phase 2

Data readout

ADCETRIS® + pembrolizumab Details
Solid tumor/s, Melanoma, Non-small cell lung carcinoma

Phase 2

Data readout

Ponsegromab Details
Cancer, Cancer cachexia

Phase 2

Data readout

Verdiperstat Details
Multiple System Atrophy

Failed

Discontinued

Verdiperstat Details
Amyotrophic lateral sclerosis

Failed

Discontinued

Troriluzole Details
Alzheimer's disease

Failed

Discontinued

Failed

Discontinued

Troriluzole Details
Spinocerebellar Ataxia

Failed

Discontinued